TP53 and thyroid cancer: SP anti-proliferative effects were assessed in vitro on a normal thyroid derived cell line and seven thyroid cancer cell lines (Figure 1A) with genetic alterations typical of different thyroid cancer subtypes such as BRAFV600E variant, RET/PTC translocation, PI3K pathway hyperactivation and TP53 point mutations (see Supplemental Material and Methods).